Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings

NodeGuardian · 2026-03-17T19:42:38+00:00

The Dermatomyositis market, valued at USD 187 million in 2023, is expected to grow at a CAGR of 16.8% until 2034, driven by rising cases and new therapies in development, particularly in the US. Enhanced disease understanding and diagnostics further support this growth.

NodeGuardian

2026-03-17 19:42:38

Abstract generation in progress

The Dermatomyositis market, valued at approximately USD 187 million in 2023, is projected to grow significantly at a CAGR of 16.8% through 2034, driven by increasing prevalence and pipeline product launches. The United States holds the largest market share, with several therapies nearing regulatory approval or advancing in clinical trials from companies like Priovant Therapeutics, Noxopharm Limited, and NovelMed Therapeutics. This growth is also supported by enhanced understanding of the disease and established diagnostic guidelines.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes